论文部分内容阅读
目的探讨厄贝沙坦片联合阿托伐他汀钙片治疗高血压肾病的临床疗效。方法选取2011—2014年魏县人民医院收治的高血压肾病患者124例,采用区组随机化分为对照组与观察组,各62例。对照组患者予以厄贝沙坦片治疗,观察组患者在对照组基础上予以阿托伐他汀钙片治疗。观察两组患者治疗前后血脂〔总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)〕、肾功能〔24h尿蛋白、血肌酐(Scr)、血尿素氮(BUN)〕、C反应蛋白(CRP)水平及不良反应发生情况。结果治疗前两组患者TC、TG、LDL、HDL、24h尿蛋白、Scr、BUN、CRP水平比较,差异无统计学意义(P>0.05),治疗后观察组患者TC、LDL、24h尿蛋白、Scr、BUN、CRP水平低于对照组,差异有统计学意义(P<0.05),两组患者TG、HDL水平比较,差异无统计学意义(P>0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论厄贝沙坦片联合阿托伐他汀钙片治疗高血压肾病的临床疗效显著,可改善患者临床症状,且不良反应少。
Objective To investigate the clinical efficacy of irbesartan tablets and atorvastatin calcium tablets in the treatment of hypertensive nephropathy. Methods A total of 124 hypertensive nephropathy patients admitted to Weixian People’s Hospital from 2011 to 2014 were randomly divided into control group and observation group with 62 patients in each group. Patients in the control group were treated with irbesartan tablets, and patients in the observation group were treated with atorvastatin calcium tablets on the basis of the control group. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL), renal function (24h urinary protein and serum creatinine (Scr) , Blood urea nitrogen (BUN)〕, C-reactive protein (CRP) levels and adverse reactions. Results The levels of TC, TG, LDL, HDL, 24h urinary protein, Scr, BUN and CRP were not significantly different between the two groups before treatment (P> 0.05) The levels of Scr, BUN and CRP in the two groups were significantly lower than those in the control group (P <0.05). There was no significant difference in TG and HDL levels between the two groups (P> 0.05). The incidence of adverse reactions , The difference was not statistically significant (P> 0.05). Conclusion The clinical efficacy of irbesartan tablets and atorvastatin calcium tablets in the treatment of hypertensive nephropathy is significant, which can improve the clinical symptoms of patients with less adverse reactions.